Fulgent Genetics Inc (FLGT, Financial) files its latest 10-K with SEC for the fiscal year ended on December 31, 2017. Fulgent Genetics Inc is a technology company offering genetic testing to provide physicians with clinically actionable diagnostic information used to improve the overall quality of patient care. Fulgent Genetics Inc has a market cap of $68.993 million; its shares were traded at around $3.87 with and P/S ratio of 3.38.
For the last quarter Fulgent Genetics Inc reported a revenue of $4.28 million, compared with the revenue of $5.85 million during the same period a year ago. For the latest fiscal year the company reported a revenue of $18.7 million, an increase of 2.5% from last year.
The reported loss per diluted share was 15 cents for the year. The Fulgent Genetics Inc had an operating margin of -18.15%, compared with the operating margin of 5.02% a year before. The 10-year historical median operating margin of Fulgent Genetics Inc is -52.34%. The profitability rank of the company is 2 (out of 10).
At the end of the fiscal year, Fulgent Genetics Inc has the cash and cash equivalents of $6.49 million, compared with $7.90 million in the previous year. The company had no long term debt. Fulgent Genetics Inc has a financial strength rank of 9 (out of 10).
At the current stock price of $3.87, Fulgent Genetics Inc is traded at 32.3% discount to its historical median P/S valuation band of $5.72. The P/S ratio of the stock is 3.38, while the historical median P/S ratio is 5.00. The stock lost 65.28% during the past 12 months.
CFO Recent Trades:
- CFO and Treasurer Paul Kim sold 1,628 shares of FLGT stock on 03/08/2018 at the average price of $3.76. The price of the stock has increased by 2.93% since.
For the complete 20-year historical financial data of FLGT, click here.
